Followers | 148 |
Posts | 17898 |
Boards Moderated | 0 |
Alias Born | 04/12/2012 |
Thursday, February 16, 2017 7:44:14 PM
By Warren Smith / in US Broker Ratings / on Wednesday, 15 Feb 2017 12:22 PM
According to the most recent research notes issued by analysts 3 analysts have outstanding research reports on Cerulean Pharma Inc. (CERU), whilst 1 of which rate the stock “Buy”, 0 “Outperform”, 0 “Underperform”, 0 “Sell”, while 2 “Hold”.
The latest updates which have been released by analysts/brokers for Cerulean Pharma Inc. (CERU) are outlined below.
10/19/2016 – Broker: Leerink Swann Rating: market perform New Target: 1.5 reiteration
10/19/2016 – Broker: Roth Capital Rating: buy New Target: 2.5 reiteration
08/30/2016 – Broker: Barclays Rating: overweight New Target: 2 reiteration
08/19/2016 – Broker: Canaccord Genuity Rating: buy New Target: 20 reiteration
08/18/2016 – Broker: JMP Securities Rating: market perform downgrade
08/18/2016 – Broker: Janney Montgomery Scott Rating: neutral New Target: 1 downgrade
08/18/2016 – Broker: Wedbush Rating: neutral New Target: 1 downgrade
05/20/2015 – Broker: Zacks Rating: buy New Target: 7 upgrade
The average target price given to the company from the latest broker reports is 5.00
The stock decreased -6.49% (-0.10) during the last days session, reaching 1.44 and roughly 3191089 shares were bought or sold by traders.
Cerulean Pharma Inc. is a clinical-stage, oncology-focused company. The Company applies its Dynamic Tumor Targeting platform to develop differentiated therapies. Its platform utilizes nanoparticle-drug conjugates (NDCs), which consist of polymers that are covalently linked to anti-cancer therapeutics or payloads. Its NDC platform is designed to create NDCs that accumulate high concentrations of active drug in tumor cells, without exposure to healthy tissue. Its platform is applicable to a range of payloads. It has created NDCs with a range of small molecule payloads, including Jevtana (cabazitaxel), gemcitabine, methotrexate and Xeljanz (tofacitinib). The Company’s product pipeline consists of CRLX101 and CRLX301. Its CRLX101 is a tumor targeted NDC. Its CRLX301 has docetaxel as its anti-cancer payload. CRLX101 has a camptothecin payload, which is a topoisomerase 1 (topo 1) inhibitor. CRLX301 is designed to concentrate docetaxel in tumor cells and spare healthy tissue.
http://www.ukmarketnews.co.uk/2017/02/15/brokers-release-average-price-target-of-5-00-on-cerulean-pharma-inc-ceru-3/
Recent DARE News
- Daré Bioscience Announces Publication in The Journal of Sexual Medicine of Positive Safety Findings from the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6% • GlobeNewswire Inc. • 08/26/2024 12:00:00 PM
- Daré Bioscience Announces Publication in The Journal of Sexual Medicine of Positive Findings from the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6% • GlobeNewswire Inc. • 08/13/2024 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/12/2024 08:05:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/12/2024 08:01:31 PM
- Daré Bioscience Reports Second Quarter 2024 Financial Results and Provides Company Update • GlobeNewswire Inc. • 08/12/2024 08:01:00 PM
- Daré Bioscience to Host Second Quarter 2024 Financial Results and Company Update Conference Call and Webcast on August 12, 2024 • GlobeNewswire Inc. • 08/05/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/19/2024 12:05:26 PM
- Daré Bioscience Regains Compliance with Nasdaq Minimum Bid Price Rule • GlobeNewswire Inc. • 07/19/2024 12:00:00 PM
- Daré Bioscience Announces Reverse Stock Split • GlobeNewswire Inc. • 06/27/2024 12:00:00 PM
- Daré Bioscience Announces Publication in Obstetrics & Gynecology of Phase 2b Study Efficacy Results of Topical Sildenafil Cream, 3.6% for the Treatment of Female Sexual Arousal Disorder • GlobeNewswire Inc. • 06/24/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 09:15:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 09:15:35 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 09:15:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/07/2024 08:05:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 08:01:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 12:05:24 PM
- Daré Bioscience Reports First Quarter 2024 Financial Results and Provides Company Update • GlobeNewswire Inc. • 05/14/2024 12:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/13/2024 04:15:35 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/10/2024 08:12:44 PM
- Daré Bioscience to Host First Quarter 2024 Financial Results and Company Update Conference Call and Webcast on May 14, 2024 • GlobeNewswire Inc. • 05/07/2024 12:00:00 PM
- Daré Bioscience Selected as a Member of ARPA-H Investor Catalyst Hub Spoke Network • GlobeNewswire Inc. • 05/02/2024 12:00:00 PM
- Daré Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women’s Health Product Candidates through Key Catalysts • GlobeNewswire Inc. • 04/30/2024 11:30:00 AM
- Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1 • GlobeNewswire Inc. • 04/23/2024 12:00:00 PM
- Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intravaginal Contraceptive • GlobeNewswire Inc. • 04/11/2024 12:00:00 PM
- Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update • GlobeNewswire Inc. • 03/28/2024 12:00:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM